A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Phase of Trial: Phase IV
Latest Information Update: 21 Feb 2019
At a glance
- Drugs Guselkumab (Primary) ; Ixekizumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms IXORA-R
- Sponsors Eli Lilly and Company
- 26 Sep 2018 Planned End Date changed from 30 Dec 2019 to 12 Nov 2019.
- 26 Sep 2018 Planned primary completion date changed from 22 Jul 2019 to 28 May 2019.
- 10 Sep 2018 According to Eli Lilly media release, Status changed from not yet recruiting to recruiting.